Seladelpar
   HOME

TheInfoList



OR:

Seladelpar (, ; developmental code names MBX-8025, RWJ-800025) is a PPARĪ“ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia,
metabolic syndrome Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Metabolic syndrome ...
, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.


See also

*
Elafibranor Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver dis ...
* GW501516 * Peroxisome proliferator-activated receptor


References


External links


Seladelpar - AdisInsight
Carboxylic acids Experimental drugs PPAR agonists Trifluoromethyl compounds {{Gastrointestinal-drug-stub